Selected transactions
To reflect healthcare trailblazers, we are shifting our focus to an integrative healthcare approach from therapeutics to personalized and preventive medicine, anti- and better-aging, healthy well-being and lifestyle.
Please find below selected transactions completed by WINDOME BANKING PARTNERS’ employees while at other Firms, except for the Suisselle-Sihuan Pharma Deal (June 2023).
Exclusive Financial Advisor to Mesotherapy leader Suisselle in the structuring of the strategic partnership for the licensing of their novel skinbooster “Cellbooster” to Chinese partner Sihuan Pharmaceuticals.
Advisor to Bridgepoint in the acquisition of a majority stake in Laboratoire Vivacy SA.
Financial Advisor to Bridgepoint in divesting a majority in HTL Biotech, a pharmaceutical-grade Hyaluronic Acid (Hyaluronan) and other Glycosaminoglycans (GAGs) and other functional Biopolymers such as PDRN or Polynucleotides (PN) to Montagu.
Outlicensing of the global rights to the Italian range of Dermocosmetics to DermaForce (the Skinbetter Science Division) for an undisclosed double-digit upfront payment, royalties and milestones.
Divestiture to AbbVie-Allergan Aesthetics for an undisclosed purchase price. Transferred brands include Crystalys, HArmonyCa, Hydryalix and Hydryal, Composite Matrix Dermal Fillers based on CAHA.
Advisor in the completion of a € 10m share capital increase and realization of a Fairness Opinion for Market Valuation.
Exclusive Financial Advisor to Nicox for the sale of the remaining stake in VISUfarma to GHO Capital.
Exclusive Financial Advisor to BMG Pharma to enter a Distribution, Supply and Licensing Agreement covering a range of Oral-Care brands with Pierre Fabre Médicament.
Share Capital Increase via preferred Convertible Offering to a consortium of new investors to support international deployment.
Exclusive Financial Advisor to Croma in the structuring of the strategic partnership for the manufacturing and supply of Menarini-Relife’s lead dermal filler Range Definisse.
Exclusive Financial Advisor to Croma in constructing a 70-30% US- based exit JV to be majority- led by Korean Toxin specialist Hugel Corporation and concurrent Divestiture of its Canadian and Australian Subsidiaries to Hugel.
Exclusive Financial Advisor to the Largest Polish Medical Aesthetic Group for the Divestiture of a 51% stake to Abris Capital, a Polish Growth Capital PE Fund and concurrent Entry into a Shareholders’ Agreement.